Prediction of isoprene diepoxide levels in vivo in mouse, rat and man using enzyme kinetic data in vitro and physiologically-based pharmacokinetic modelling.

The present study was designed to explain the differences in isoprene toxicity between mouse and rat based on the liver concentrations of the assumed toxic metabolite isoprene diepoxide. In addition, extrapolation to the human situation was attempted. For this purpose, enzyme kinetic parameters K(m) and V(max) were determined in vitro in mouse, rat and human liver microsomes/cytosol for the cytochrome P450-mediated formation of isoprene mono- and diepoxides, epoxide hydrolase mediated hydrolysis of isoprene mono- and diepoxides, and the glutathione S-transferases mediated conjugation of isoprene monoepoxides. Subsequently, the kinetic parameters were incorporated into a physiologically-based pharmacokinetic model, and species differences regarding isoprene diepoxide levels were forecasted. Almost similar isoprene diepoxide liver and lung concentrations were predicted in mouse and rat, while predicted levels in humans were about 20-fold lower. However, when interindividual variation in enzyme activity was introduced in the human model, the levels of isoprene diepoxide changed considerably. It was forecasted that in individuals having both an extensive oxidation by cytochrome P450 and a low detoxification by epoxide hydrolase, isoprene diepoxide concentrations in the liver increased to similar concentrations as predicted for the mouse. However, the interpretation of the latter finding for human risk assessment is ambiguous since species differences between mouse and rat regarding isoprene toxicity could not be explained by the predicted isoprene diepoxide concentrations. We assume that other metabolites than isoprene diepoxide or different carcinogenic response might play a key role in determining the extent of isoprene toxicity. In order to confirm this, in vivo experiments are required in which isoprene epoxide concentrations will be established in rats and mice.

[1]  H. Bolt,et al.  Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. , 1994, The Biochemical journal.

[2]  J. A. Bond,et al.  Physiologically based pharmacokinetic modeling of 1,3-butadiene, 1,2-epoxy-3-butene, and 1,2:3,4-diepoxybutane toxicokinetics in mice and rats. , 1997, Carcinogenesis.

[3]  P. Gervasi,et al.  Hepatic microsomal metabolism of isoprene in various rodents. , 1985, Toxicology letters.

[4]  M. Pirmohamed,et al.  Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene. , 1996, The Journal of pharmacology and experimental therapeutics.

[5]  M E Andersen,et al.  Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. , 1989, Toxicology and applied pharmacology.

[6]  P. Thomas,et al.  Human liver microsomal epoxide hydrolase. Correlation of immunochemical quantitation with catalytic activity. , 1982, Molecular pharmacology.

[7]  M C Kohn,et al.  The privileged access model of 1,3-butadiene disposition. , 2000, Environmental health perspectives.

[8]  R. Pero,et al.  Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. , 1990, Carcinogenesis.

[9]  M. Metzler,et al.  Possible role of oxygen radicals in cell transformation by diethylstilbestrol and related compounds. , 1986, Carcinogenesis.

[10]  H. Ragan,et al.  Isoprene, an endogenous hydrocarbon and industrial chemical, induces multiple organ neoplasia in rodents after 26 weeks of inhalation exposure. , 1994, Cancer research.

[11]  J. A. Bond,et al.  Disposition of inhaled isoprene in B6C3F1 mice. , 1991, Toxicology and applied pharmacology.

[12]  P. van Bladeren,et al.  The biotransformation of isoprene and the two isoprene monoepoxides by human cytochrome P450 enzymes, compared to mouse and rat liver microsomes. , 1996, Chemico-biological interactions.

[13]  H. Ragan,et al.  Inhalation toxicology of isoprene in F344 rats and B6C3F1 mice following two-week exposures. , 1990, Environmental health perspectives.

[14]  J. Filser,et al.  PBPK model for butadiene metabolism to epoxides: quantitative species differences in metabolism. , 1996, Toxicology.

[15]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[16]  J. A. Bond,et al.  The role of hydrolysis in the detoxification of 1,2:3,4-diepoxybutane by human, rat, and mouse liver and lung in vitro. , 1996, Toxicology and applied pharmacology.

[17]  J. A. Bond,et al.  In vivo metabolism of butadiene by mice and rats: a comparison of physiological model predictions and experimental data. , 1994, Carcinogenesis.

[18]  C. J. Omiecinski,et al.  Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. , 1997, Archives of Biochemistry and Biophysics.

[19]  W. P. Watson,et al.  Metabolism and molecular toxicology of isoprene. , 2001, Chemico-biological interactions.

[20]  P. Gervasi,et al.  Metabolism and mutagenicity of isoprene. , 1990, Environmental health perspectives.

[21]  P. Gervasi,et al.  Isoprene metabolism by liver microsomal mono-oxygenases. , 1985, Xenobiotica; the fate of foreign compounds in biological systems.

[22]  R. Weaver,et al.  Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  J. A. Bond,et al.  Comparison of the biotransformation of 1,3-butadiene and its metabolite, butadiene monoepoxide, by hepatic and pulmonary tissues from humans, rats and mice. , 1992, Carcinogenesis.

[24]  P. J. Bladeren,et al.  Conjugation of isoprene monoepoxides with glutathione, catalyzed by α, μ, π and θ-class glutathione S-transferases of rat and man , 1999 .

[25]  K. Weigand,et al.  Stereoselectivity of in vitro isoprene metabolism. , 1994, Chemical research in toxicology.

[26]  J. A. Bond,et al.  Glutathione conjugation of 1,2:3,4- diepoxybutane in human liver and rat and mouse liver and lung in vitro. , 1996, Toxicology and applied pharmacology.

[27]  G. Talaska,et al.  The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. , 1992, Environmental health perspectives.

[28]  M E Andersen,et al.  A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.